BACKGROUND: The protein kinase ataxia telangiectasia mutated (ATM) mediates cellular response to DNA damage induced by radiation. ATM inhibition decreases DNA damage repair in tumor cells and affects tumor growth. AZD1390 is a novel, highly potent, selective ATM inhibitor designed to cross the blood-brain barrier (BBB) and currently evaluated with radiotherapy in a phase I study in patients with brain malignancies. In the present study, PET was used to measure brain exposure of 11C-labeled AZD1390 after intravenous (i.v.) bolus administration in healthy subjects with an intact BBB. METHODS: AZD1390 was radiolabeled with carbon-11 and a microdose (mean injected mass 1.21 µg) was injected in 8 male subjects (21-65 y). The radioactivity concentration of [11C]AZD1390 in brain was measured using a high-resolution PET system. Radioactivity in arterial blood was measured to obtain a metabolite corrected arterial input function for quantitative image analysis. Participants were monitored by laboratory examinations, vital signs, electrocardiogram, adverse events. RESULTS: The brain radioactivity concentration of [11C]AZD1390 was 0.64 SUV (standard uptake value) and reached maximum 1.00% of injected dose at Tmax[brain] of 21 min (time of maximum brain radioactivity concentration) after i.v. injection. The whole brain total distribution volume was 5.20 mL*cm-3. No adverse events related to [11C]AZD1390 were reported. CONCLUSIONS: This study demonstrates that [11C]AZD1390 crosses the intact BBB and supports development of AZD1390 for the treatment of glioblastoma multiforme or other brain malignancies. Moreover, it illustrates the potential of PET microdosing in predicting and guiding dose range and schedule for subsequent clinical studies.
BACKGROUND: The protein kinase ataxia telangiectasia mutated (ATM) mediates cellular response to DNA damage induced by radiation. ATM inhibition decreases DNA damage repair in tumor cells and affects tumor growth. AZD1390 is a novel, highly potent, selective ATM inhibitor designed to cross the blood-brain barrier (BBB) and currently evaluated with radiotherapy in a phase I study in patients with brain malignancies. In the present study, PET was used to measure brain exposure of 11C-labeled AZD1390 after intravenous (i.v.) bolus administration in healthy subjects with an intact BBB. METHODS:AZD1390 was radiolabeled with carbon-11 and a microdose (mean injected mass 1.21 µg) was injected in 8 male subjects (21-65 y). The radioactivity concentration of [11C]AZD1390 in brain was measured using a high-resolution PET system. Radioactivity in arterial blood was measured to obtain a metabolite corrected arterial input function for quantitative image analysis. Participants were monitored by laboratory examinations, vital signs, electrocardiogram, adverse events. RESULTS: The brain radioactivity concentration of [11C]AZD1390 was 0.64 SUV (standard uptake value) and reached maximum 1.00% of injected dose at Tmax[brain] of 21 min (time of maximum brain radioactivity concentration) after i.v. injection. The whole brain total distribution volume was 5.20 mL*cm-3. No adverse events related to [11C]AZD1390 were reported. CONCLUSIONS: This study demonstrates that [11C]AZD1390 crosses the intact BBB and supports development of AZD1390 for the treatment of glioblastoma multiforme or other brain malignancies. Moreover, it illustrates the potential of PET microdosing in predicting and guiding dose range and schedule for subsequent clinical studies.
Authors: Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-13 Impact factor: 9.236
Authors: B T Christian; E Livni; J W Babich; N M Alpert; D D Dischino; E Ruediger; D E Salazar; N F Ford; A J Fischman Journal: J Pharmacol Exp Ther Date: 1996-10 Impact factor: 4.030
Authors: Michal Bahar; Hasan Hashem; Tanya Tekautz; Sarah Worley; Anne Tang; Peter de Blank; Johannes Wolff Journal: J Neurooncol Date: 2017-03-13 Impact factor: 4.130
Authors: Andrea Varrone; Katarina Varnäs; Aurelija Jucaite; Zsolt Cselényi; Peter Johnström; Magnus Schou; Ana Vazquez-Romero; Mohammad M Moein; Christer Halldin; Andrew P Brown; Karthick Vishwanathan; Lars Farde Journal: J Cereb Blood Flow Metab Date: 2019-04-20 Impact factor: 6.200
Authors: Catherine Hanna; Kathreena M Kurian; Karin Williams; Colin Watts; Alan Jackson; Ross Carruthers; Karen Strathdee; Garth Cruickshank; Laurence Dunn; Sara Erridge; Lisa Godfrey; Sarah Jefferies; Catherine McBain; Rebecca Sleigh; Alex McCormick; Marc Pittman; Sarah Halford; Anthony J Chalmers Journal: Neuro Oncol Date: 2020-12-18 Impact factor: 12.300
Authors: Irena Loryan; Andreas Reichel; Bo Feng; Christoffer Bundgaard; Christopher Shaffer; Cory Kalvass; Dallas Bednarczyk; Denise Morrison; Dominique Lesuisse; Edmund Hoppe; Georg C Terstappen; Holger Fischer; Li Di; Nicola Colclough; Scott Summerfield; Stephen T Buckley; Tristan S Maurer; Markus Fridén Journal: Pharm Res Date: 2022-04-11 Impact factor: 4.580
Authors: Peter H Goff; Rashmi Bhakuni; Thomas Pulliam; Jung Hyun Lee; Evan T Hall; Paul Nghiem Journal: Cancers (Basel) Date: 2021-07-08 Impact factor: 6.639